1. Signaling Pathways
  2. GPCR/G Protein
  3. Somatostatin Receptor

Somatostatin Receptor

Somatostatin receptor is a family of G protein-coupled seven transmembrane receptors. Somatostatin acts at many sites to inhibit the release of many hormones and other secretory proteins. The biological effects of somatostatin are probably mediated by a family of G protein-coupled receptors that are expressed in a tissue-specific manner. Include SSTR1, SSTR2, SSTR3, SSTR4, SSTR5. SSTR1 is expressed in highest levels in jejunum and stomach. SSTR2 is a member of the superfamily of receptors having seven transmembrane segments and is expressed in highest levels in cerebrum and kidney. SSTR3 is functionally coupled to adenylyl cyclase. SSTR4 is a member of the superfamily of receptors having seven transmembrane segments and is expressed in highest levels in fetal and adult brain and lung. SSTR5 is a member of the superfamily of receptors having seven transmembrane segments.

Somatostatin Receptor Related Products (12):

Cat. No. Product Name Effect Purity
  • HY-17365
    Octreotide acetate Agonist 99.78%
    Octreotide acetate, a long-acting synthetic analog of native somatostatin, inhibits growth hormone, glucagon, and insulin more potently.
  • HY-79135
    Pasireotide ditrifluoroacetate
    Pasireotide (ditrifluoroacetate) is a stable cyclohexapeptide somatostatin mimic that exhibits unique high-affinity binding to human somatostatin receptors (subtypes sst1/2/3/4/5, pKi=8.2/9.0/9.1/<7.0/9.9, respectively).
  • HY-13466
    MK-4256 Antagonist 98.63%
    MK-4256 is a potent and selective SSTR3 antagonist with IC50s of 0.66 nM and 0.36 nM in human and mouse receptor binding assays, respectively.
  • HY-P0036
    Octreotide Agonist 99.15%
    Octreotide is a somatostatin analog that binds to the somatostatin receptor, mainly subtypes 2, 3, and 5, increases Gi activity, and reduces intracellular cAMP production.
  • HY-79136
    Pasireotide L-aspartate salt 99.44%
    Pasireotide(SOM 230) is a stable cyclohexapeptide somatostatin mimic that exhibits unique high-affinity binding to human somatostatin receptors (subtypes sst1/2/3/4/5, pKi=8.2/9.0/9.1/<7.0/9.9 respectively).
  • HY-P1202A
    CYN 154806 TFA Antagonist 99.97%
    CYN 154806 (TFA), a cyclic octapeptide, is a potent and selective somatostatin sst2 receptor antagonist, with pIC50 values of 8.58, 5.41, 6.07, 5.76 and 6.48 for human recombinant sst2, sst1, sst3, sst4 and sst5 receptors respectively.
  • HY-114191
    SSTR5 antagonist 2 Antagonist
    SSTR5 antagonist 2 (compound 10) is a highly potent, oral active and selective somatostatin (receptor) subtype 5 (SSTR5) antagonist and has potential to treat type 2 diabetes mellitus (T2DM).
  • HY-114191A
    SSTR5 antagonist 2 TFA Antagonist
    SSTR5 Antagonist 1 (compound 10) is a highly potent, oral active and selective somatostatin (receptor) subtype 5 (SSTR5) antagonist and has potential to treat type 2 diabetes mellitus (T2DM).
  • HY-P0061A
    Vapreotide acetate 99.61%
    Vapreotide acetate is a synthetic analog of somatostatin for the treatment of variceal bleeding; also exhibits antitumor activity. Sequence: Phe-Cys-Tyr-Trp-Lys-Val-Cys-Trp-NH2(Disulfide bridge: Cys2-Cys7).
  • HY-16381
    Pasireotide
    Pasireotide(SOM 230) is a stable cyclohexapeptide somatostatin mimic that exhibits unique high-affinity binding to human somatostatin receptors (subtypes sst1/2/3/4/5, pKi=8.2/9.0/9.1/<7.0/9.9 respectively).
  • HY-102037
    SSTR5 antagonist 1 Antagonist
    SSTR5 antagonist 1 is a potent, selective, and orally available somatostatin receptor subtype 5 (SSTR5) antagonist with IC50s of 9.6 and 57 nM for hSSTR5 and mSSTR5, respectively. (Compound 25a)
  • HY-P1202
    CYN 154806 Antagonist
    CYN 154806, a cyclic octapeptide, is a potent and selective somatostatin sst2 receptor antagonist, with pIC50 values of 8.58, 5.41, 6.07, 5.76 and 6.48 for human recombinant sst2, sst1, sst3, sst4 and sst5 receptors respectively.
Isoform Specific Products

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.